Our technology is the bridge that transforms promising peptides into long-acting therapeutics.
Enabling technologies for the efficient and sustained delivery of peptides and proteins
Extend Biosciences Inc. is a clinical stage biotechnology company developing a novel drug delivery platform technology that improves the pharmacokinetic properties of peptides and proteins.
Peptides have been particularly challenging to bring to market because they are removed from circulation prior to administering therapeutic value.
Our proprietary D-VITylation® platform technology significantly improves the circulating half-life and bioavailability of peptides and proteins, enabling the development potent and specific drugs.
Cancer Cachexia
Cachexia is a complex metabolic syndrome characterized by involuntary weight loss and skeletal muscle wasting that impairs response to drug treatment and is associated with a poor prognosis. More than half of all cancer patients develop cachexia and it is responsible for more than 20% of all deaths. Currently, there are no FDA-approved treatments for cachexia.
Learn More
HypoPARAthyroidism
Hypoparathyroidism is a rare disorder that causes low levels of calcium in the blood due to insufficient levels of parathyroid hormone. The current standard of care is supplementation with calcium and vitamin D, but this does not correct the underlying hormone deficiency, and long term, patients experience renal function deterioration, among other issues.
Learn MoreD-VITylation® Technology
Our proprietary D-VITylation® platform technology significantly improves the circulating half-life and bioavailability of peptides and proteins, enabling the development potent and specific drugs.
Learn More
About Us
The founders of Extend Biosciences conceived the D-VITylation technology after working on the problem of half-life extension in the biotech/pharma industry.
Learn More